Impact Factor 4.416

Frontiers journals are at the top of citation and impact metrics

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2018.00516

Simultaneous 18F-fluciclovine Positron Emission Tomography and Magnetic Resonance Spectroscopic Imaging of Prostate Cancer

  • 1Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Norway
  • 2Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Netherlands
  • 3Department of Surgical Operations, St Olav's University Hospital, Norway
  • 4Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Norway
  • 5Department of Radiology and Nuclear Medicine, St Olav's University Hospital, Norway

Purpose: To investigate the associations of metabolite levels derived from magnetic resonance spectroscopic imaging (MRSI) and 18F-fluciclovine positron emission tomography (PET) with prostate tissue characteristics. Methods: In a cohort of 19 high-risk prostate cancer patients that underwent simultaneous PET/MRI, we evaluated the diagnostic performance of MRSI and PET for discrimination of aggressive cancer lesions from healthy tissue and benign lesions. Data analysis comprised calculations of correlations of mean standardized uptake values (SUVmean), maximum SUV (SUVmax), and the MRSI-derived ratio of (total choline + spermine + creatine) to citrate (CSC/C). Whole-mount histopathology was used as gold standard. Results: The results showed a moderate significant correlation between both SUVmean and SUVmax with CSC/C ratio. Conclusions: We demonstrated that the simultaneous acquisition of 18F-fluciclovine PET and MRSI with an integrated PET/MRI system is feasible and a combination of these imaging modalities has potential to improve the diagnostic sensitivity and specificity of prostate cancer lesions.

Keywords: positron emission tomography, Magnetic Resonance Spectroscopy, Benign prostatic hyperplasia (BPH), Chemical shift imaging (CSI), Citrate, prostate cancer

Received: 19 Jul 2018; Accepted: 22 Oct 2018.

Edited by:

Marie-France Penet, School of Medicine, Johns Hopkins University, United States

Reviewed by:

Naranamangalam R. Jagannathan, All India Institute of Medical Sciences, India
Ellen Ackerstaff, Memorial Sloan Kettering Cancer Center, United States  

Copyright: © 2018 Esmaeili, Tayari, Scheenen, Elschot, Sandsmark, Bertilsson, Heerschap, Selnæs and Bathen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Morteza Esmaeili, Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, 7491, Sør-Trøndelag, Norway,